Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Publication date: 9 October 2017
Source:Cancer Cell, Volume 32, Issue 4
Author(s): Eric G. Bluemn, Ilsa M. Coleman, Jared M. Lucas, Roger T. Coleman, Susana Hernandez-Lopez, Robin Tharakan, Daniella Bianchi-Frias, Ruth F. Dumpit, Arja Kaipainen, Alexandra N. Corella, Yu Chi Yang, Michael D. Nyquist, Elahe Mostaghel, Andrew C. Hsieh, Xiaotun Zhang, Eva Corey, Lisha G. Brown, Holly M. Nguyen, Kenneth Pienta, Michael Ittmann, Michael Schweizer, Lawrence D. True, David Wise, Paul S. Rennie, Robert L. Vessella, Colm Morrissey, Peter S. Nelson
Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and represents the major therapeutic target for treating metastatic prostate cancer (mPC). Though highly effective, AR antagonism can produce tumors that bypass a functional requirement for AR, often through neuroendocrine (NE) transdifferentiation. Through the molecular assessment of mPCs over two decades, we find a phenotypic shift has occurred in mPC with the emergence of an AR-null NE-null phenotype. These "double-negative" PCs are notable for elevated FGF and MAPK pathway activity, which can bypass AR dependence. Pharmacological inhibitors of MAPK or FGFR repressed the growth of double-negative PCs in vitro and in vivo. Our results indicate that FGF/MAPK blockade may be particularly efficacious against mPCs with an AR-null phenotype.

Teaser

Bluemn et al. show that androgen receptor (AR) inhibition results in a phenotypic shift in castration-resistant prostate cancer, leading to tumors that are AR-null but not neuroendocrine (NE). Models for AR-null, non-NE tumors show elevated FGF and MAPK activity and are sensitive to blockade of these pathways.


from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2yDxEWd